Search results for "oligonucleotide"

showing 10 items of 418 documents

From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs.

2015

Asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis, are among the most common chronic diseases and their prevalence is increasing. Each of these diseases is characterized by the secretion of cytokines and pro-inflammatory molecules which are thought to play a critical role in their pathogenesis. Moreover, immune cells, particularly neutrophils, macrophages and dendritic cells as well structural cells such as epithelial and airway smooth muscle cells are also involved in the pathogenic cycle of these diseases. There is a pressing need for the development of new therapies for these pulmonary diseases, particularly as no existing treatment has bee…

0301 basic medicineSmall interfering RNARespiratory diseasessiRNA deliveryHMGB1 (high-mobility group box 1)medicine.medical_treatmentGenetic enhancementOligonucleotidesPharmaceutical Science02 engineering and technologyBiologySmall InterferingPathogenesis03 medical and health sciencesIdiopathic pulmonary fibrosisImmune systemRNA interferenceNucleic AcidsmedicineAnimalsHumansAntisenseHMGB1 ProteinRNA Small InterferingCatalyticLungNABDs deliveryDNADNA CatalyticGenetic TherapyOligonucleotides Antisense021001 nanoscience & nanotechnologymedicine.diseaseRespiration Disorders030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyChronic DiseaseRNAInflammation Mediators0210 nano-technologyHMGB1 (high-mobility group box 1); Inflammation mediators; NABDs delivery; Respiratory diseases; siRNA delivery; Animals; Chronic Disease; DNA Catalytic; HMGB1 Protein; Humans; Inflammation Mediators; Nucleic Acids; Oligonucleotides Antisense; RNA Small Interfering; Respiration Disorders; Genetic TherapyCurrent drug delivery
researchProduct

MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.

2016

This article will review the impact of the recently developed MassARRAY technology on our understanding of cancer biology and treatment. Analysis of somatic mutations is a useful tool in selecting personalized therapy, and for predicting the outcome of many solid tumors. Here, we review the literature on the application of MassARRAY technology (Sequenom Hamburg, Germany) to determine the mutation profile of solid tumors from patients. We summarize the use of commercially available panels of mutations - such as OncoCarta™ or other combinations - and their concordance with results obtained by using other technologies, such as next generation sequencing.

0301 basic medicineSomatic cellConcordanceComputational biologymedicine.disease_causeBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsMedicineHumansRadiology Nuclear Medicine and imagingCancer biologyPersonalized therapyPrecision MedicineOligonucleotide Array Sequence AnalysisMutationbusiness.industryHigh-Throughput Nucleotide SequencingGeneral MedicineOncogenesPrecision medicine030104 developmental biologyOncology030220 oncology & carcinogenesisMutationPersonalized medicinebusinessCancer treatment reviews
researchProduct

A detailed experimental study of a DNA computer with two endonucleases

2017

Abstract Great advances in biotechnology have allowed the construction of a computer from DNA. One of the proposed solutions is a biomolecular finite automaton, a simple two-state DNA computer without memory, which was presented by Ehud Shapiro’s group at the Weizmann Institute of Science. The main problem with this computer, in which biomolecules carry out logical operations, is its complexity – increasing the number of states of biomolecular automata. In this study, we constructed (in laboratory conditions) a six-state DNA computer that uses two endonucleases (e.g. AcuI and BbvI) and a ligase. We have presented a detailed experimental verification of its feasibility. We described the effe…

0301 basic medicineTheoretical computer scienceDNA LigasesComputer scienceCarry (arithmetic)Oligonucleotides0102 computer and information sciencesBioinformatics01 natural sciencesGeneral Biochemistry Genetics and Molecular Biologylaw.inventionAutomationComputers Molecular03 medical and health sciencesDNA computinglawA-DNADeoxyribonucleases Type II Site-Specificchemistry.chemical_classificationDNA ligaseFinite-state machineBase Sequencebiomolecular computers; DNA computing; finite automataProcess (computing)DNAModels TheoreticalEndonucleasesAutomaton030104 developmental biologychemistry010201 computation theory & mathematicsWord (computer architecture)Zeitschrift für Naturforschung C
researchProduct

Dom34 Links Translation to Protein O-mannosylation.

2016

In eukaryotes, Dom34 upregulates translation by securing levels of activatable ribosomal subunits. We found that in the yeast Saccharomyces cerevisiae and the human fungal pathogen Candida albicans, Dom34 interacts genetically with Pmt1, a major isoform of protein O-mannosyltransferase. In C. albicans, lack of Dom34 exacerbated defective phenotypes of pmt1 mutants, while they were ameliorated by Dom34 overproduction that enhanced Pmt1 protein but not PMT1 transcript levels. Translational effects of Dom34 required the 5′-UTR of the PMT1 transcript, which bound recombinant Dom34 directly at a CA/AC-rich sequence and regulated in vitro translation. Polysomal profiling revealed that Dom34 stimu…

0301 basic medicineUntranslated regionCancer ResearchGlycosylationMolecular biologyHydrolasesOligonucleotidesGene ExpressionRNA-binding proteinCell Cycle ProteinsYeast and Fungal ModelsPathology and Laboratory MedicineMannosyltransferasesBiochemistryTranscription (biology)Untranslated RegionsCandida albicansMedicine and Health SciencesProtein IsoformsGenetics (clinical)CandidaFungal PathogensNucleotidesMessenger RNACell biologyEnzymesNucleic acidsDenaturationPhenotypesPhenotypeMedical MicrobiologySaccharomyces CerevisiaePathogensResearch ArticleGene isoformSaccharomyces cerevisiae Proteinslcsh:QH426-470NucleasesSaccharomyces cerevisiaeMycologyBiologyResearch and Analysis MethodsMicrobiology03 medical and health sciencesSaccharomycesModel OrganismsRibonucleasesDownregulation and upregulationEndoribonucleasesDNA-binding proteinsGeneticsHumansGeneMicrobial PathogensEcology Evolution Behavior and Systematics030102 biochemistry & molecular biologyOrganismsFungiBiology and Life SciencesProteinsRibosomal RNAbiology.organism_classificationMolecular biologyYeastRNA denaturationlcsh:Genetics030104 developmental biologyMolecular biology techniquesProtein BiosynthesisEnzymologyRNAProtein TranslationRibosomesPLoS Genetics
researchProduct

In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment

2016

Abstract: An in silico pathway analysis was performed in order to improve current knowledge on the molecular drivers of cervical cancer and detect potential targets for treatment. Three publicly available Affymetrix gene expression data-sets (GSE5787, GSE7803, GSE9750) were retrieved, vouching for a total of 9 cervical cancer cell lines (CCCLs), 39 normal cervical samples, 7 CIN3 samples and 111 cervical cancer samples (CCSs). Predication analysis of microarrays was performed in the Affymetrix sets to identify cervical cancer biomarkers. To select cancer cell-specific genes the CCSs were compared to the CCCLs. Validated genes were submitted to a gene set enrichment analysis (GSEA) and Expre…

0301 basic medicineUterine Cervical NeoplasmMAPK3Uterine Cervical NeoplasmsBioinformaticsHeLa CellMitogen-Activated Protein Kinase0302 clinical medicineTransforming Growth Factor betaMedicineOligonucleotide Array Sequence AnalysisCancerCervical cancerABLCell CycleIn silico pathway analysiCell cycleGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisFemaleDNA microarrayMitogen-Activated Protein KinasesTreatment targetResearch PaperHumanin silico pathway analysisMAP Kinase Signaling SystemIn silicoComputational biologytreatment targetsProto-Oncogene Proteins c-myc03 medical and health sciencesCell Line TumorBiomarkers TumorHumansComputer SimulationAmino Acid SequenceBiologyCervical carcinomabusiness.industryOligonucleotide Array Sequence AnalysiGene Expression ProfilingCancerComputational Biologymedicine.diseaseChromatin Assembly and DisassemblyGene expression profiling030104 developmental biologyHuman medicinebusinessHeLa CellsOncotarget
researchProduct

Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for parkinson’s disease

2018

Progressive neuronal death in brainstem nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson’s disease (PD). Reduction of α-synuclein levels is therefore a potential therapy for PD. However, because α-synuclein is essential for neuronal development and function, α-synuclein elimination would dramatically impact brain function. We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration. Here, we used this strategy to conjugate inhibitory oligonucleotides, siRNA and antisense oligonucleotide (ASO), with the triple monoamine reuptake …

0301 basic medicineanimal diseasesDopamineOligonucleotidesGene ExpressionPharmacologySynaptic TransmissionPrefrontal cortexMiceDA neurotransmission0302 clinical medicineDrug DiscoveryMonoaminergicNeural PathwaysRNA Small InterferingCells Cultured5-HT neurotransmissionChemistryGene Transfer TechniquesParkinson DiseaseVentral tegmental areaSubstantia Nigramedicine.anatomical_structureCaudate putamenGene Knockdown Techniquesalpha-SynucleinMolecular MedicineRNA InterferenceOriginal ArticleMonoamine reuptake inhibitormedicine.drugSignal TransductionSerotoninSubstantia nigraASO03 medical and health sciencesProsencephalonα-synucleinDopamineIntranasal administrationGeneticsmedicineAnimalsHumansMolecular BiologyAdministration IntranasalPharmacologyPars compactaDopaminergic NeuronsGenetic TherapyCorpus Striatumnervous system diseases030104 developmental biologyMonoamine neurotransmitterGene Expression Regulationnervous systemsiRNAParkinson’s diseaseLocus coeruleus030217 neurology & neurosurgery
researchProduct

Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

2017

Antonio Miguel,1 Luis Sendra,1 Verónica Noé,2 Carles J Ciudad,2 Francisco Dasí,3,4 David Hervas,5 María José Herrero,1,6 Salvador F Aliño17 1Department of Pharmacology, Faculty of Medicine, University of Valencia, 2Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Barcelona, 3Research University Hospital of Valencia, INCLIVA Health Research Institute, 4Department of Physiology, Faculty of Medicine, University of Valencia Foundation, 5Biostatistics Unit, 6Pharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 7Clinical Pharmacology Unit, ACM Hospital Univers…

0301 basic medicineantisense oligonucleotidemedicine.medical_treatmentCellImmunoteràpiaIpilimumabchemical and pharmacologic phenomenaImmunotheraphyVacuneslcsh:RC254-282OncoTargets and Therapy03 medical and health sciencesgene silencingCancer immunotherapymedicineGene silencingPharmacology (medical)IL-2 receptorCàncerOriginal ResearchTumorsCancerVaccinescancer immunotherapybiologybusiness.industryFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVaccinationTreg030104 developmental biologymedicine.anatomical_structureantitumor vaccineOncologybiology.proteinCancer researchAntibodybusinessmedicine.drugOncoTargets and Therapy
researchProduct

Micro-RNA profile and proteins in peritoneal fluid from women with endometriosis: their relationship with sterility.

2018

Objective: To define the microRNA (miRNA) profile and its relationship with cytokines content in peritoneal fluid (PF) from endometriosis patients. Design: Case-control study. Setting: University hospital, research institute. Patient(s): One hundred twenty-six women with endometriosis (EPF) and 45 control women (CPF). Main Outcomes Measure(s): MiRNA arrays were prepared from six EPF and six CPF. Quantitative reverse transcription-polymerase chain reaction validation of nine selected miRNAs (miR-29c-3p, -106b-3p, -130a-3p, -150-5p, -185-5p, -195-5p, -451a, -486-5p, and -1343-5p) was performed. Vascular endothelial growth factor-A (VEGF-A), thrombospondin-1 (TSP-1), urokinase plasminogen acti…

0301 basic medicineendometriosisAdultProteomicsMMP3AngiogenesisEndometriosisEndometriosisEnzyme-Linked Immunosorbent AssayAndrology03 medical and health sciences0302 clinical medicinePregnancymedicineAscitic FluidHumansAngiogenic ProteinsMacrophage inflammatory proteinOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicinemicroRNAbusiness.industryPeritoneal fluidGene Expression ProfilingObstetrics and GynecologyInterleukinProteinsMiddle Agedmedicine.diseaseFold changeMicroRNAs030104 developmental biologyperitoneal fluidFertilityReproductive MedicineinflammationCase-Control StudiesCytokinesFemaleAngiogenesisInflammation MediatorsbusinessTranscriptomePlasminogen activatorInfertility FemaleFertility and sterility
researchProduct

Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives

2020

Background: Early and accurate diagnosis of endometriosis is crucial for the management of this benign, yet debilitating pathology. Despite the advances of modern medicine, there is no common ground regarding the pathophysiology of this disease as it continues to affect the quality of life of millions of women of reproductive age. The lack of specific symptoms often determines a belated diagnosis. The gold standard remains invasive, surgery followed by a histopathological exam. A biomarker or a panel of biomarkers is easy to measure, usually noninvasive, and could benefit the clinician in both diagnosing and monitoring the treatment response. Several studies have advanced the idea of biomar…

0301 basic medicineendometriosisProteomicsEndometriosisDiseaseReviewlcsh:ChemistryangiogenesisEndometrium0302 clinical medicinelcsh:QH301-705.5SpectroscopyOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicineNeovascularization PathologicGeneral MedicineGenomicsComputer Science ApplicationsBiomarker (medicine)biomarkerFemalemedicine.medical_specialtyTreatment responseModern medicineCatalysisInorganic Chemistry03 medical and health sciencesmedicineHumansMetabolomicsurinary biomarkersPhysical and Theoretical ChemistryIntensive care medicineMolecular BiologyNoninvasive biomarkersAutoantibodiesInflammationbusiness.industryOrganic ChemistryGold standard (test)medicine.diseaseUrinary biomarkerscytokinesMicroRNAsOxidative Stress030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessPeptidesBiomarkersInternational Journal of Molecular Sciences
researchProduct

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy

2020

Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. The expansion becomes pathogenic when DMPK transcripts contain 50 or more repetitions due to the sequestration of the muscleblind-like (MBNL) family of proteins. Depletion of MBNLs causes alterations in splicing patterns in transcripts that contribute to clinical symptoms such as myotonia and muscle weakness and wasting. We previously found that microRNA (miR)-23b directly regulates MBNL1 in DM1 myoblasts and mice and that antisense technology (“antagomiRs”) blocking this microRNA (miRNA) boost…

0301 basic medicinemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesMyotonic dystrophyArticleantagomiR03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoverymicroRNAMedicineMBNL1AntagomirProtein kinase AmiRNAmyotonic dystrophybusiness.industrylcsh:RM1-950Muscle weaknessmedicine.diseaseMyotoniaMbnl1030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisRNA splicingCancer researchHSALR miceMolecular Medicinemedicine.symptomDM1antisense oligonucleotidesbusinessMolecular Therapy: Nucleic Acids
researchProduct